Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan

2020, Volume 14, Issue 2

Abstract

Keywords

Related Research

Frontiers of Medicine >> 2020, Volume 14, Issue 2 doi: 10.1007/s11684-020-0757-x

Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19 in Wuhan

. Division of Cardiology;.. Division of Respiration, Department of Internal Medicine and Hubei Key Laboratory of Genetics and Molecular Mechanisms of Cardiological Disorders, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

Accepted: 2020-03-16 Available online: 2020-03-16

HTML33 PDF 28 Collect 0

Next Previous

Abstract

In December 2019, an outbreak of novel coronavirus (2019-nCoV) occurred in Wuhan, Hubei Province, China. By February 14, 2020, it has led to 66 492 confirmed patients in China and high mortality up to ~2.96% (1123/37 914) in Wuhan. Here we report the first family case of coronavirus disease 2019 (COVID-19) confirmed in Wuhan and treated using the combination of western medicine and Chinese traditional patent medicine Shuanghuanglian oral liquid (SHL). This report describes the identification, diagnosis, clinical course, and management of three cases from a family, suggests the expected therapeutic effects of SHL on COVID-19, and warrants further clinical trials.

Keywords

novel coronavirus (2019-nCoV) ; COVID-19 ; Chinese traditional patent medicine ; Shuanghuanglian oral liquid

Related Research